PharmaBoardroom’s Top 5 Op-Eds in 2021 (So Far)

main_img

As our thoughts here at PharmaBoardroom turn towards the summer holidays, we are happy to share the five most-read articles from our global contributor network so far in 2021. These thought leadership pieces cover topics as vital and diverse as the latest regulatory updates from China; EU-UK pharma trade; the skills needed to manage in MEA; opportunities for the life science industry in Australia post-COVID; and market entry opportunities and challenges in Japan. Enjoy reading, and see you on the beach!

China’s National Reimbursement Drug List (NRDL) 2020: What Reward for Innovation?

Vaccine Wars: What the EU/AstraZeneca Row Shows Us About Pharma Cross-Border Litigation

The Skills That Regional Pharma Leaders Need in the Middle East & Africa

Opportunities for the Life Science Industry in Australia post-COVID

Japan Market Entry: Opportunities & Challenges


Related Content


Latest Report